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Diabetic retinopathy (DR) is an increasingly frequent cause
of blindness across populations; however, the events that
initiate pathophysiology of DR remain elusive. Strong preclinical and clinical evidence suggests that abnormalities in
retinal lipid metabolism caused by diabetes may account for
the origin of this disease. A major arm of lipid metabolism,
de novo biosynthesis, is driven by elevation in available glucose,
a common thread binding all forms of vision loss in diabetes.
Therefore, we hypothesized that aberrant retinal lipid biogenesis is an important promoter of early DR. In murine models,
we observed elevations of diabetes-associated retinal de novo
lipogenesis 70% over control levels. This shift was primarily
because of activation of fatty acid synthase (FAS), a ratelimiting enzyme in the biogenic pathway. Activation of FAS
was driven by canonical glucose-mediated disinhibition of
acetyl-CoA carboxylase, a major upstream regulatory enzyme.
Mutant mice expressing gain-of-function FAS demonstrated
increased vulnerability to DR, whereas those with FAS deletion
in rod photoreceptors maintained preserved visual responses
upon induction of diabetes. Excess retinal de novo lipogenesis
—either because of diabetes or because of FAS gain of function
—was associated with modestly increased levels of palmitatecontaining phosphatidylcholine species in synaptic membranes, a ﬁnding with as yet uncertain signiﬁcance. These
ﬁndings implicate glucose-dependent increases in photoreceptor de novo lipogenesis in the early pathogenesis of DR,
although the mechanism of deleterious action of this pathway
remains unclear.

Therapy for diabetic retinopathy (DR), a common cause of
visual disability, has evolved greatly over the past 2 decades but
remains ineffective for up to one-third of patients (1). Development of new strategies for treatment could be facilitated by
gaining better insight into the pathophysiology of early stage
DR. Abnormalities in retinal lipid metabolism occur early in
the course of diabetes and are therefore attractive candidates
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for mediation of mechanisms that eventually result in vision
loss (2).
Retinal lipid abnormalities in diabetes involve both accumulation of deleterious lipids as well as depletion of beneﬁcial
ones. Strategies to correct such abnormalities have the potential to lower risk of vision loss from diabetes. For example,
reversal of cholesterol accumulation in retinas of streptozotocin (STZ)-induced diabetic mice using liver X receptor agonists reduces severity of DR (3). Similarly, lowering of retinal
ceramide levels in diabetes by inhibiting acid sphingomyelinase
activity (4) prevents vascular degeneration (5). Complex and
very long chain polyunsaturated fatty acids (VLC-PUFA),
including docosahexaenoic acid (DHA) and eicosapentaenoic
acid, are disproportionately abundant in the retina compared
with other tissues (6, 7) and are needed to maintain retinal
health but are reduced by diabetes (8, 9). In experimental
models, dietary PUFA replacement reduces DR severity (10),
and in a randomized clinical trial, DHA supplementation was
associated with lower DR severity scores (11).
Photoreceptors, which are increasingly recognized loci of
early DR pathogenesis (12), are particularly susceptible to
perturbations in membrane lipid composition—speciﬁcally
because of defects in biosynthetic machinery. For example,
reduction of photoreceptor DHA because of targeted
disruption of the biosynthetic enzyme lysophosphatidic acid
acyltransferase 3 resulted in synaptic dysmorphology and
vision loss (13). Diabetes also reduces DHA biosynthesis
because of downregulation of elongation of VLC fatty acids
protein 4 (ELOVL4), whereas ELOV4 overexpression can
counteract some of the effects of diabetes on the retina (14).
More broadly, lipid derangements because of disruption of
rod photoreceptor fatty acid synthase (FAS)—the enzyme
that catalyzes the committed step of de novo lipogenesis
(15)—causes loss of retinal DHA and VLC-PUFAs, resulting
in a rapid neurodegeneration (16). FAS is a multifunctional
enzyme made up of eight individual catalytic centers, and it
generates palmitate (C16:0) from malonyl-CoA and acetylCoA using NADPH as a cofactor. This pathway is essential
for multiple arms of cellular lipid biosynthesis, including
those responsible for VLC fatty acid production (16).
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Diabetes is associated with tissue-speciﬁc changes in FAS,
which may be root causes of its complications (17, 18). In
macrophages, FAS dysfunction in diabetes results in rearrangement of plasma membrane fatty acids, causing
impaired or aberrant cellular signaling (19). In skeletal
muscle, FAS activity and expression are increased in the
setting of insulin resistance, causing increased saturation
index of membrane lipids (20). However, the effects of diabetes on this important and elemental lipid biogenesis
pathway in the retina are incompletely described. Here, we
describe studies examining changes to FAS enzyme activity
during diabetes, effects of FAS manipulation on DR phenotypes, and associated changes to the retinal lipid landscape
during experimental diabetes.

Results
Diabetes is associated with elevated activity of retinal de
novo lipogenesis
To investigate whether ﬂux through de novo lipogenesis is
affected by diabetes, we performed enzyme activity assays in
retinal tissues for FAS. We used three independent models of
diabetes—leptin receptor–deﬁcient mice (db/db), high-fat
diet (HFD)–induced disease, and STZ-induced disease (two
models of type 2 diabetes and one type 1 model)—that are all
associated with progressive retinal dysfunction and dysmorphology (21–23). After 3 months of exposure to diabetes in all models, de novo lipogenesis was assessed by
measuring the incorporation of radiolabeled malonyl-CoA
precursor into palmitate—a reaction uniquely catalyzed by
FAS. The controls for these experiments were healthy littermates of the diseased animals (db/m as controls for db/db,
chow-fed mice for the HFD model, and vehicle-injected mice
in the STZ model). Across all three models, diabetes was
associated with 70% increase in retinal FAS activity
compared with controls (Fig. 1A). Since carbohydrate availability is an important determinant of biosynthetic ﬂux, we
next performed in vitro assays using short-term retinal explants derived from 3-month-old healthy WT mice to
determine the effect of glucose on retinal FAS activity.
Exposure of retinal tissue to high glucose (25 mM D-glucose)
for 6 h caused an 60% increase in FAS activity compared
with an osmotically balanced low glucose control medium
(5 mM D-glucose + 20 mM L-glucose) (Fig. 1B). These increases were similar to the effects of insulin (100 ng/ml),
which is known to positively modulate FAS activity through
allosteric effects (Fig. 1B).
To determine whether diabetes caused elevated FAS activity
via changes in Fasn mRNA or protein levels, we performed
Western blotting and quantitative PCR in retinal tissues. FAS
protein levels were unchanged between healthy retinas or
those exposed to one of three forms of experimental diabetes
(Fig. 1, C and D). Similarly, a 6-h-high glucose pulse or insulin
treatment was not associated with changes in FAS protein
expression or RNA levels in retinal explants (Fig. 1, E–G).
Whereas db/db retinas contained elevated messenger RNA
levels of reactive factors, such as inducible nitric oxide
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synthase (INOS) and glial ﬁbrillary acidic protein (GFAP), they
had similar Fasn messenger RNA levels as control db/m tissue
(Fig. 1H).
These results suggest that elevated FAS activity in the retina
during diabetes is caused by a post-translational mechanism
and is responsive to elevated glucose alone. We therefore
examined the properties of acetyl Co-A carboxylase (ACC) in
the diabetic retina since this enzyme is activated by elevated
cellular glucose concentration and acts as an important
regulator of FAS activity by regulating the production of its
necessary substrate, malonyl-CoA. ACC undergoes inhibitory
phosphorylation under conditions of low cellular glucose and
conversely becomes dephosphorylated in high glucose concentrations (24). In all three models of experimental diabetes,
we found that ACC was hypophosphorylated relative to
healthy controls, indicative of increased retinal ACC activity in
diabetes (Fig. 1, I and J).
Rod photoreceptors are the predominant source of retinal FAS
activity
We next characterized mice carrying genetic modiﬁcations
at the Fasn locus causing loss-of-function (LOF) and gain-offunction (GOF) phenotypes. In prior studies, we showed that
homozygous deletion of Fasn from the neural retina (Fasnﬂ/ﬂ;
Chx10-Cre-driven loxp recombination) was associated with a
rapid and early onset neurodegeneration, making this reagent
unsuitable for a long-term DR modeling experiment (16).
Instead, we generated Fasnﬂ/+;Chx10-Cre+/− (“retina LOF”), as
these heterozygotes do not have any discernible baseline
phenotype. These mice demonstrated a 50% reduction in
FAS protein level in the retina compared with controls,
consistent with our prior observations, and a concomitant
50% reduction in FAS enzyme activity compared with controls (Fig. 2, A–C). Since rod photoreceptors make up >80% of
the cell population in the mouse retina, we also generated
mutants with targeted heterozygous loss of rod FAS using the
i75-Cre transgene (Fasnﬂ/+;i75-Cre+/−; “rod LOF”) (25). These
mice showed nearly identical losses in FAS protein level and
enzyme activity as retina LOF mice (Fig. 2, A–C), suggesting
that rod photoreceptors are the predominant cellular loci of
retinal de novo lipogenesis. After induction of diabetes with
HFD for 3 months, retina LOF and rod LOF mice have 50%
less FAS enzyme activity than controls on HFD and are on par
with non–diabetes mellitus controls, indicating that both LOF
mutants effectively neutralize the retinal FAS activity gains
caused by chronic HFD (Fig. 2D).
FAS GOF variant
We also characterized baseline retinal phenotypes of mice
with homozygous knock-in of a GOF FAS variant associated
with human intellectual disability and impaired adult neurogenesis (26). This variant, which results in a single amino
acid substitution of tryptophan for arginine at residue 1812
in mice and 1819 in humans (R1812W), demonstrates a
50% increase in enzymatic activity compared with the WT
control in brain tissue (27). Similarly, we found that mice

Fatty acid synthase drives early diabetic retinopathy

Figure 1. Increased rate of de novo lipogenesis in the diabetic retina. A, using a radiolabel incorporation assay that interrogates fatty acid synthase (FAS)
function, rates of de novo lipogenesis were measured from whole retinal extracts derived from animals after 3 months of exposure to DM in three different
models (high-fat diet feeding, HFD; leptin receptor mutants, db/db; or streptozotocin-induced, STZ) or from healthy littermates. B, FAS activity in retinal
explants derived from 3-month-old WT animals and cultured for 6 h in control media (5 mM D-glucose + 20 mM L-glucose), high glucose (25 mM D-glucose),
or high insulin (5 mM D-glucose + 20 mM L-glucose + 100 ng/ml insulin). C and D, Western blots and quantiﬁcation for FAS or a loading control (Akt) from
retinal extracts derived from animals with diabetes (db/db; STZ injected) or their healthy controls (db/m; vehicle treated). E and F, Western blots and
quantiﬁcation for FAS or Akt from retinal explant cultures in control, high glucose, or high insulin conditions for 6 h. G, quantitative polymerase chain
reaction for Fasn from retinal explants cultured for 6 h in control media or media containing either high glucose or high insulin. H, quantitative polymerase
chain reaction from retinal extracts of db/db mice or healthy db/m controls for the gene targets indicated. I and J, Western blots and quantiﬁcation for
phosphorylated acetyl co-A carboxylase (ACC) or a total ACC from retinal extracts derived from animals with diabetes (db/db; HFD; STZ injected) or their
healthy controls (db/m; chow fed; vehicle treated). Data represent mean with interquartile range (box) and range (whiskers) and were analyzed by Student’s t
test (A, D, G, and J) or one-way ANOVA (B, F, and H). *p < 0.05, **p < 0.01, and ***p < 0.001. DM, diabetes mellitus.
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Figure 2. Manipulation of retinal FAS activity using loss-of-function and gain-of-function approaches. A and B, Western blots and quantiﬁcation for
FAS from retinal extracts of C57Bl/6J mice (WT), Fasnﬂ/+;Chx10-Cre+/− mice (retina LOF), FasnR1812W/R1812W mice (GOF), or Fasnﬂ/+; i75-Cre+/− mice (rod LOF). C,
FAS activity from retinal extracts of WT, retina LOF, rod LOF, or GOF mice. D, retinal FAS activity from WT, retina LOF, rod LOF, or GOF mice with 3 months of
exposure to high-fat diet–induced DM compared with healthy WT mice (non-DM). E, representative hematoxylin and eosin–stained parafﬁn cross sections
of retinas from control, retina LOF, and GOF mice with the indicated genotypes and (F) quantiﬁcation of retinal thicknesses as measured as distances from
the nerve ﬁber layer (NFL) to retinal pigment epithelium (RPE). B–D, data represent mean with interquartile range (box) and range (whiskers) and were
analyzed by one-way ANOVA. F, data represent mean with SEM and were analyzed by two-way ANOVA. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p <
0.0001. DM, diabetes mellitus; FAS, fatty acid synthase; GOF, gain of function; LOF, loss of function.

carrying this variant have 50% elevation in retinal FAS
activity compared with controls but with no associated increase in protein expression (Fig. 2, A–C). Interestingly, the
GOF mice showed no additive increase in enzyme activity
after induction of diabetes compared with controls (Fig. 2D).
Even at 12 months of age, we did not observe any degenerative changes or other gross morphological phenotype in
retina LOF, rod LOF, or GOF mutants compared with controls (Fig. 2, E and F).
Effects of FAS reduction in rods on DR phenotypes
We next assessed whether DR phenotypes are affected by
FAS rod LOF mice. After HFD induction, we performed
electroretinography (ERG) to assess scotopic oscillatory
potential (OP) characteristics—features that are associated
with early retinal damage in human diabetes and features
that our group has shown to precede the onset of typical
vascular lesions in this mouse model (23). Whereas HFD for
6 months causes increased latency of OP timing across all
four major peaks and loss of OP amplitudes compared with
nondiabetic littermates in control animals, such changes
were not seen in mice with FAS rod LOF (Fig. 3, A–C).
Similar to our previous observations, HFD does not impact
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scotopic a-wave or b-wave amplitudes, and background FAS
rod LOF does not change this feature of the ERG (Fig. 3, D
and E). These results argue that diabetes-speciﬁc ERG deﬁcits in HFD-fed mice are reversible by partial loss of FAS
activity. To conﬁrm that the protective changes extended
beyond ERG effects, we performed quantitative PCR for gene
products that are known to react to diabetes-induced stress
in the retina. Whereas HFD-fed mice had elevated
messenger RNA levels of vascular endothelial growth factora, intercellular adhesion molecule 1, INOS and GFAP, rod
LOF mice on HFD had no such elevations compared with
rod LOF on chow diet or compared with control mice on
chow diet (Fig. 3F).
Effects of FAS GOF on retinal function in diabetes
Using mice homozygous for the FAS R1812W variant, we
induced diabetes by HFD and measured retinal function by
scotopic ERG. As previously observed, we found that HFD
was associated with loss of OP amplitudes, without effects on
a-wave or b-wave amplitudes, and only at 6 months of
exposure to disease but not at an earlier time point (Fig. 4,
A–F). FAS GOF on HFD showed no changes in this pattern
of disease expression and did not impact the severity of OP
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Figure 3. Effects of FAS haploinsufﬁciency in rod photoreceptors on diabetes-induced electroretinographic deﬁcits and reactive gene expression.
A, representative oscillatory potential (OP) waveforms from scotopic electroretinograms after a 0.25 cd⋅s/m2 white ﬂash showing four major peaks (OP 1–4)
in control animals (Fasn+/+; i75-Cre+/−) or rod LOF (Fasnﬂ/+; i75-Cre+/−) mice that were subjected to high-fat diet (HFD)–induced diabetes mellitus (DM) or
standard chow feeding (non-DM). B, luminance-response curves of normalized scotopic OP amplitudes in control mice or mice with FAS rod LOF, comparing
HFD-induced DM or non-DM (chow-fed) conditions. C, scotopic OP implicit times (latencies) after a 0.25 cd⋅s/m2 white ﬂash for each major peak in non-DM
mice or those with HFD-induced DM. D, scotopic a-wave luminance-response curves and (E) b-wave luminance response curves from the indicated groups,
represented as normalized ratios of the maximal ﬂash amplitude after a 7.863 cd⋅s/m2 stimulus. F, quantitative polymerase chain reaction for the gene
targets indicated from retinal extracts of mice after 12 months of exposure to HFD-induced DM or under healthy chow-fed condition (non-DM) controls. B,
D, and E, data represent mean with SEM and were analyzed by two-way ANOVA. C and F, data represent mean with interquartile range (box) and range
(whiskers) and were analyzed by one-way ANOVA. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. In panel B, *p < 0.05 comparing “control NON
DM” to “control DM”; ††p < 0.01 comparing “control DM” to “Fas Rod Het DM.” FAS, fatty acid synthase; LOF, loss of function.

amplitude loss at 6 months compared with controls (Fig. 4F).
However, while FAS GOF showed similar delays in OP
timing after 6 months of HFD exposure compared with
controls, we also observed such delays after 3 months of
HFD exposure when control animals had not yet manifested
the phenotype (Fig. 4, G and H). FAS GOF mice on chow diet

showed no difference in ERG characteristics compared with
WT controls on chow diet at any age tested (up to
12 months). Together, these results suggest that elevated
FAS activity alone is insufﬁcient to reproduce the effects of
diabetes on retinal function loss, but that it does accelerate
such effects.
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Figure 4. Effects of FAS gain-of-function on retinal function during the course of high-fat diet–induced diabetes. Scotopic a-wave luminanceresponse curves, represented as normalized ratios of the maximal ﬂash amplitude after a 7.863 cd⋅s/m2 stimulus, at 3 months (A) and 6 months (B) after DM induction in control mice or mice carrying the FAS R1812W gain-of-function (GOF) polymorphism. Normalized b-wave luminance-response curves at
3 months (C) and 6 months (D) after DM induction in control or GOF mice. Luminance-response curves of normalized scotopic oscillatory potential (OP)
amplitudes at 3 months (E) and 6 months (F) after DM induction in control and GOF mice. Scotopic OP implicit times (latencies) after a 0.25 cd⋅s/m2 white
ﬂash for each major peak in non-DM mice or those with HFD-induced DM after 3 months of exposure (G) or 6 months of exposure (H) to experimental diet,
and with or without FAS GOF. A–F, data represent mean with SEM and were analyzed by two-way ANOVA. G and H, data represent mean with interquartile
range (box) and range (whiskers) and were analyzed by one-way ANOVA. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. In panel F, *p < 0.05,
****p < 0.0001 comparing “WT NON DM” to “WT DM”; ††††p < 0.0001 comparing “FAS R1812W NON DM” to “FAS R1812W DM.” DM, diabetes mellitus; FAS,
fatty acid synthase.

6 J. Biol. Chem. (2021) 297(3) 101104

Fatty acid synthase drives early diabetic retinopathy
Effects of diabetes and elevated FAS activity on retinal
synaptic lipids
Our observations with FAS mutants on DR phenotypes in
mice suggest that abnormally elevated activity of this enzyme
directly contributes to the pathogenesis of vision loss in diabetes. To explore a potential mechanism, we performed lipid
surveys of isolated retinal synaptic membranes, as these
structures are highly susceptible to changes in retinal FAS
activity (16). Among sucrose gradient fractions enriched for
retinal synaptic membranes, we observed an increase in
phosphatidylcholines (PCs) containing saturated fatty acids
(SFAs)—speciﬁcally those with C16:0—in diabetic db/db mice
compared with nondiabetic db/m littermate controls (Table 1).
In addition, diabetic samples had lower relative content of PCs
with unsaturated fatty acids and long alkyl chains (>20 C)
compared with nondiabetic controls, consistent with observations performed by others using whole-retina extracts. After
performing the same analysis in samples from FAS GOF mice
(nondiabetic) and comparing to WT control tissue, we found
that excess FAS activity caused a 4% elevation of retinal synaptic dipalmitoyl-PC (DPPC, PC 16:0/16:0) (Table 2). Of note,
FAS GOF mice did not have any relative depletion of PUFAcontaining PCs and, on the contrary, had elevated levels of
PC 22:6/22:6 compared with controls (Table 2). The changes
we observed in synaptic membrane content in diabetic mice
were speciﬁc, since no observed differences were seen among
lyso-PCs (Table 3). In FAS GOF, we observed a moderate

increase in lyso-PCs 32:6 compared with WT controls
(Table 4). We observed no changes in phosphatidylethanolamines (PEs) over controls in tissues from diabetic mice
(Table 5) or FAS GOF mice (Table 6).

Discussion
Vision loss from DR commonly occurs because of a progressive vasculopathy that has well-deﬁned ophthalmoscopic
characteristics (28). However, damage to the retina in diabetes
occurs long before the onset of such lesions and likely involves
numerous nonvascular cell types of the retina, notably photoreceptors. In preclinical models, inactivating mutations in
components of the rod visual cycle (including Rho, RPE65, and
Gnat1), pharmacologic blockade of RPE65, or prolonged visual
sensory deprivation are all associated with reduction in DR
severity or even outright prevention of any detectable DR
(29–32). Taken together with the long-recognized unique
metabolic demands of photoreceptors (33), these observations
strongly implicate perturbations in photoreceptor and/or visual cycle metabolism as a key initiating event in the pathogenesis of DR. The current study provides insight into a
putative role for an arm of photoreceptor metabolism—that of
de novo lipogenesis regulated by FAS—as one such molecular
pathway altered by diabetes. In type 1 and type 2 models of
diabetes, elevated retinal FAS activity was associated with
hyperglycemia and disinhibition of ACC, a proximal regulatory
enzyme. Nearly, all the excess de novo lipogenic activities in

Table 1
Changes in normalized retinal synaptic membrane PC content associated with experimental diabetes
PC species
14:0/16:1
14:0/16:0
p16:0/16:1
a16:0/16:1
16:1/16:1
16:0/16:1
16:0/16:0
p16:0/18:1
a16:0/18:1
16:1/18:2
16:0/18:2; 16:1/18:1
16:0/18:1
p16:0/20:4
a16:0/20:4
a18:0/18:1
16:0/20:4
16:0/20:3; 18:1/18:2
18:1/18:1; 18:0/18:2
16:0/22:6
18:0/18:1
p18:0/20:4
a18:0/20:4
18:1/20:4; 16:0/22:5
18:0/20:4
18:1/22:6
18:0/22:6
18:0/22:5
18:0/22:4
42:10
42:4
22:6/22:6
22:6/32:6
22:6/34:6
22:5/24:6
22:6/34:6

Control (95% conﬁdence interval); n = 6
0.061
0.043
0.006
0.018
0.011
0.157
1.012
0.026
0.022
0.012
0.104
0.354
0.020
0.016
0.019
0.109
0.055
0.128
0.509
0.427
0.014
0.012
0.102
0.163
0.061
0.658
0.103
0.335
0.174
0.008
0.151
0.027
0.027
0.018
0.003

(0.057–0.065)
(0.040–0.046)
(0.005–0.007)
(0.016–0.019)
(0.010–0.013)
(0.152–0.162)
(0.981–1.043)
(0.024–0.028)
(0.022–0.023)
(0.011–0.013)
(0.098–0.109)
(0.348–0.360)
(0.019–0.022)
(0.015–0.018)
(0.017–0.020)
(0.103–0.116)
(0.053–0.057)
(0.124–0.131)
(0.485–0.532)
(0.395–0.458)
(0.013–0.016)
(0.010–0.014)
(0.099–0.106)
(0.149–0.176)
(0.059–0.062)
(0.594–0.721)
(0.094–0.113)
(0.305–0.364)
(0.163–0.185)
(0.007–0.009)
(0.145–0.157)
(0.025–0.028)
(0.025–0.029)
(0.016–0.020)
(0.003–0.004)

Diabetes (95% conﬁdence interval); n = 6
0.069
0.041
0.007
0.022
0.014
0.163
1.015
0.034
0.022
0.015
0.124
0.356
0.022
0.016
0.017
0.102
0.058
0.122
0.472
0.428
0.015
0.013
0.097
0.149
0.061
0.666
0.106
0.335
0.178
0.006
0.153
0.023
0.021
0.014
0.002

(0.067–0.071)
(0.039–0.044)
(0.007–0.008)
(0.021–0.024)
(0.013–0.015)
(0.159–0.167)
(0.982–1.048)
(0.032–0.037)
(0.021–0.023)
(0.013–0.016)
(0.113–0.134)
(0.347–0.365)
(0.020–0.023)
(0.014–0.018)
(0.015–0.019)
(0.099–0.105)
(0.054–0.062)
(0.119–0.125)
(0.459–0.486)
(0.423–0.432)
(0.014–0.015)
(0.012–0.014)
(0.095–0.099)
(0.145–0.153)
(0.058–0.065)
(0.638–0.694)
(0.102–0.110)
(0.322–0.348)
(0.167–0.189)
(0.005–0.007)
(0.137–0.168)
(0.020–0.026)
(0.018–0.025)
(0.012–0.015)
(0.002–0.003)

p
0.004
0.425
0.012
0.002
0.007
0.109
0.896
0.0006
0.996
0.009
0.007
0.764
0.401
0.771
0.166
0.075
0.187
0.030
0.025
0.953
0.621
0.746
0.046
0.092
0.771
0.809
0.653
0.977
0.642
0.026
0.856
0.050
0.019
0.006
0.003

Synaptic membranes isolated by sucrose gradient were analyzed by electrospray ionization mass spectrometry. Identiﬁed peaks were normalized to input protein content and to an
internal standard. Mice were either 6-month-old db/db (diabetes) or littermate db/m (control). Groups were compared by two-tailed homoscedastic t test.
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Table 2
Changes in normalized retinal synaptic membrane PC content associated with FAS GOF
PC species

Control (95% conﬁdence interval); n = 6

14:0/16:1
14:0/16:0
p16:0/16:1
a16:0/16:1
16:1/16:1
16:0/16:1
16:0/16:0
p16:0/18:1
a16:0/18:1
16:1/18:2
16:0/18:2; 16:1/18:1
16:0/18:1
p16:0/20:4
a16:0/20:4
a18:0/18:1
16:0/20:4
16:0/20:3; 18:1/18:2
18:1/18:1; 18:0/18:2
p18:0/20:4
a18:0/20:4
16:0/22:6
18:0/18:1
18:1/20:4;16:0/22:5
18:0/20:4
18:1/22:6
18:0/22:6
18:0/22:5
40:4
42:10
42:4
22:6/22:6
22:6/32:6
22:6/34:6
22:5/34:6
22:6/36:6

0.067
0.039
0.007
0.021
0.011
0.155
0.957
0.036
0.023
0.011
0.097
0.345
0.017
0.014
0.017
0.107
0.053
0.113
0.013
0.011
0.449
0.414
0.091
0.161
0.052
0.583
0.095
0.030
0.015
0.007
0.087
0.018
0.020
0.013
0.003

(0.060–0.074)
(0.037–0.041)
(0.007–0.008)
(0.019–0.022)
(0.010–0.013)
(0.149–0.162)
(0.946–0.969)
(0.033–0.038)
(0.022–0.025)
(0.010–0.013)
(0.092–0.010)
(0.339–0.351)
(0.015–0.019)
(0.012–0.016)
(0.015–0.018)
(0.097–0.117)
(0.051–0.055)
(0.110–0.116)
(0.011–0.015)
(0.009–0.013)
(0.437–0.461)
(0.410–0.419)
(0.088–0.094)
(0.149–0.173)
(0.051–0.054)
(0.566–0.600)
(0.092–0.097)
(0.029–0.031)
(0.014–0.017)
(0.007–0.008)
(0.081–0.092)
(0.017–0.019)
(0.018–0.022)
(0.012–0.014)
(0.002–0.003)

FAS GOF (95% conﬁdence interval); n = 6
0.060
0.042
0.006
0.020
0.010
0.145
0.998
0.033
0.022
0.011
0.097
0.355
0.016
0.014
0.017
0.093
0.052
0.108
0.011
0.011
0.446
0.399
0.087
0.142
0.054
0.576
0.090
0.029
0.013
0.007
0.100
0.017
0.018
0.012
0.003

(0.057–0.064)
(0.041–0.043)
(0.006–0.007)
(0.019–0.021)
(0.008–0.012)
(0.139–0.151)
(0.988–1.010)
(0.031–0.035)
(0.020–0.023)
(0.010–0.012)
(0.092–0.102)
(0.348–0.361)
(0.015–0.017)
(0.013–0.015)
(0.015–0.019)
(0.090–0.097)
(0.050–0.055)
(0.104–0.113)
(0.010–0.012)
(0.009–0.013)
(0.418–0.473)
(0.387–0.411)
(0.083–0.091)
(0.137–0.147)
(0.052–0.056)
(0.547–0.605)
(0.086–0.095)
(0.028–0.030)
(0.011–0.015)
(0.005–0.008)
(0.094–0.105)
(0.015–0.018)
(0.015–0.021)
(0.009–0.014)
(0.002–0.003)

p
0.129
0.062
0.062
0.514
0.171
0.039
0.0003
0.135
0.153
0.858
0.994
0.052
0.351
0.860
0.648
0.025
0.529
0.113
0.104
0.906
0.827
0.043
0.089
0.018
0.114
0.690
0.146
0.032
0.051
0.233
0.006
0.255
0.232
0.314
0.523

Synaptic membranes isolated by sucrose gradient were analyzed by electrospray ionization mass spectrometry. Identiﬁed peaks were normalized to input protein content and to an
internal standard. Mice were either 6-month-old Fasn+/+ (control) or age-matched FasnR1812W/R1812W (FAS GOF). Groups were compared by two-tailed homoscedastic t test.

the diabetic retina were attributed to rod FAS, whereas targeted loss of FAS in rods mitigated DR-associated scotopic OP
amplitude reductions and implicit time delays. Furthermore,
we linked elevated FAS activity to increased palmitate content
within retinal synaptic membranes, similar to changes seen
with diabetes alone.
Our observations are consistent with those of others
studying lipid dysmetabolism in the diabetic retina, but some
important distinctions deserve attention. Similar to Busik
et al., we found that retinal membranes from diabetic mice
were relatively depleted of DHA-containing phospholipids
(Table 1). In their studies, retinal DHA reductions in diabetes
were linked to lowered expression of ELOVL2 and ELOVL4,
although the mechanism for suppressed expression of these
factors remains unclear (9). Unlike these investigators, we
found that several SFA-containing species—particularly those

with palmitate (C16:0), such as DPPC—were elevated in DR,
albeit modestly. Whereas prior studies examined changes in
lipid landscapes because of diabetes in whole-retina extracts,
we examined isolated retinal synaptic membranes. This key
difference in methodology likely accounts for the disparity
between our observations compared with a prior study that did
not ﬁnd changes in SFA content in DR (9).
We chose to study lipid compositions in retinal synaptic
membranes for two reasons. First, in our earlier studies of de
novo lipogenesis in the retina, we found that retinal synaptic
membranes were particularly affected by FAS depletion, which
was associated with reductions in synaptic SFAs and loss of
ribbon architecture (16). In mice with homozygous deletion of
Fasn, we did not observe a depletion of DPPC in whole-retina
extracts. However, after repeating the analysis in gradient
fractions enriched for synaptic membranes, we found marked

Table 3
Changes in normalized retinal synaptic membrane lyso-PC content associated with experimental diabetes
Lyso-PC species

Control (95% conﬁdence interval); n = 6

16:0
18:1
18:0
20:0
22:6
32:6

0.296
0.139
0.137
0.027
0.190
0.026

(0.221–0.371)
(0.103–0.176)
(0.106–0.167)
(0.021–0.034)
(0.144–0.236)
(0.024–0.029)

Diabetes (95% conﬁdence interval); n = 6
0.850
0.391
0.392
0.075
0.538
0.071

(−0.216
(−0.085
(−0.087
(−0.019
(−0.131
(−0.017

to
to
to
to
to
to

1.916)
0.867)
0.870)
0.169)
1.207)
0.159)

p
0.333
0.325
0.322
0.345
0.333
0.344

Synaptic membranes isolated by sucrose gradient were analyzed by electrospray ionization mass spectrometry. Identiﬁed peaks were normalized to input protein content and to an
internal standard. Mice were either 6-month-old db/db (diabetes) or littermate db/m (control). Groups were compared by two-tailed homoscedastic t test.
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Table 4
Changes in normalized retinal synaptic membrane lyso-PC content associated with FAS GOF
Lyso-PC species
16:0
18:1
18:0
20:0
22:6
32:6

Control (95% conﬁdence interval); n = 6
2.747
1.384
1.272
0.272
1.494
0.181

(2.178–3.315)
(1.098–1.669)
(1.003–1.541)
(0.216–0.328)
(1.197–1.792)
(0.100–0.262)

FAS GOF (95% conﬁdence interval); n = 6
2.807
1.300
1.380
0.226
1.487
0.349

(2.359–3.255)
(1.089–1.511)
(1.124–1.635)
(0.193–0.259)
(1.239–1.736)
(0.227–0.470)

p
0.874
0.655
0.582
0.202
0.973
0.048

Synaptic membranes isolated by sucrose gradient were analyzed by electrospray ionization mass spectrometry. Identiﬁed peaks were normalized to input protein content and to an
internal standard. Mice were either 6-month-old Fasn+/+ (control) or age-matched FasnR1812W/R1812W (FAS GOF). Groups were compared by two-tailed homoscedastic t test.

reductions in DPPC in animals lacking retinal FAS. Consistent
with these earlier ﬁndings, we now found that FAS GOF mice
had elevated levels of DPPC within retinal synapses (Table 2).
Second, our current ﬁndings argue that FAS enzyme changes
in diabetes affect ERG function early in the course of disease—
pointing to a potential impact on retinal synaptic health. This
possibility is feasible since lipid content determines membrane
biophysical characteristics, including effects on ﬂuidity and
deformability, which can strongly inﬂuence synaptic function
(34). However, because the lipid changes we observed in
synapses were modest, other changes to the retinal lipid
environment—such as alterations in retinal triglyceride content or to lipid droplet formation in the outer retina—deserve
further study as putative pathogenic mechanisms in FAS GOF
mice.
Importantly, we did not observe a DR-related phenotype (or
any structural or functional phenotype) in FAS GOF mice in
the absence of background diabetes. This result suggests that
overactivity of FAS (on the order of 50% elevation) is insufﬁcient to produce ERG changes related to DR. Instead, we found
that scotopic OP delays occurred in an accelerated fashion in
FAS GOF mice on HFD compared with WT mice on HFD
(3 months versus 6 months) (Fig. 4). One explanation accounting for these ﬁndings is that elevated retinal enzyme activity in FAS GOF mice is not high enough to reproduce the
effect of diabetes. Another explanation is that FAS activity increases are one of many diabetes-associated changes in photoreceptors that initiate early DR. Such a model would account
for our ﬁnding that retinas from FAS GOF mice had elevated

levels of VLC-PUFA (PC-22:6/22:6 and lyso-PC-32:6, Tables 2
and 4) compared with WT controls, in contrast with tissues
from diabetic mice, which showed relative loss of VLC-PUFA
compared with nondiabetic controls (Table 1). We propose
that combinatorial effects of SFA accumulation because of FAS
overactivity with other retinal membrane modiﬁcations in
diabetes, such as loss of VLC-PUFA because of decreased
ELOVL4 or stearyl-CoA desaturase activity, could cause the
necessary lipid pathology needed to initiate DR (Fig. 5).
Although the evidence for a photoreceptor locus of early
pathology in DR is compelling—including some evidence from
patients with inherited retinal degeneration from
photoreceptor-inactivating polymorphisms—the link between
such changes and the eventual development of typical vascular
lesions in DR are unclear (35–37). Data from Busik et al.
suggest that the loss of VLC-PUFA in diabetes may not be at
the level of photoreceptors—even though photoreceptor outer
segments are known to have the highest concentration of these
lipids. Instead, they propose that endothelial PUFA loss,
causing changes in biomechanics of membranes in the vicinity
of claudin-5 complexes, could compromise tight-junction
physiology and lead to barrier dysfunction (14). Another
possibility is that diabetes-induced lipid perturbations at
photoreceptor synapses directly impact neurovascular
coupling (38). These effects could be mediated by changes in
synaptic membrane ﬂuidity and subsequent effects on neurotransmission (34). Also possible is that excess retinal SFA
could have deleterious consequences on photoreceptor energy
metabolism, which could in turn impact vascular coupling

Table 5
Changes in normalized retinal synaptic membrane PE content associated with experimental diabetes
PE species
16:0/16:1
16:0/18:2
16:0/18:1
p16:0/20:4
16:0/20:4
18:1/18:1
18:0/18:1
p16:0/22:6
p16:0/22:5
p18:0/20:4
16:0/22:6
18:1/20:4
18:0/20:3
p18:0/22:6
18:1/22:6
18:0/22:4

Control (95% conﬁdence interval); n = 6
0.017
0.014
0.034
0.248
0.052
0.032
0.128
0.399
0.152
0.275
0.705
0.149
0.107
0.525
0.199
0.147

(0.011–0.023)
(0.005–0.022)
(0.024–0.044)
(0.176–0.321)
(0.040–0.064)
(0.023–0.042)
(0.090–0.166)
(0.314–0.483)
(0.122–0.183)
(0.227–0.323)
(0.647–0.764)
(0.120–0.177)
(0.082–0.131)
(0.411–0.639)
(0.166–0.231)
(0.111–0.183)

Diabetes (95% conﬁdence interval); n = 6
0.022
0.012
0.068
0.338
0.052
0.039
0.099
0.421
0.206
0.420
0.759
0.195
0.067
0.684
0.238
0.192

(0.003–0.040)
(0.008–0.016)
(0.055–0.081)
(0.296–0.381)
(0.036–0.069)
(0.024–0.053)
(0.080–0.118)
(0.359–0.484)
(0.179–0.232)
(0.341–0.498)
(0.637–0.881)
(0.152–0.237)
(0.040–0.094)
(0.631–0.737)
(0.194–0.281)
(0.139–0.244)

p
0.608
0.711
0.002
0.062
0.984
0.487
0.207
0.684
0.026
0.011
0.456
0.109
0.058
0.032
0.190
0.197

Synaptic membranes isolated by sucrose gradient were analyzed by electrospray ionization mass spectrometry. Identiﬁed peaks were normalized to input protein content and to an
internal standard. Mice were either 6-month-old db/db (diabetes) or littermate db/m (control). Groups were compared by two-tailed homoscedastic t test.
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Table 6
Changes in normalized retinal synaptic membrane PE content associated with FAS GOF
PE species

Control (95% conﬁdence interval); n = 6

16:0/16:1
16:0/18:2
16:0/18:1
p16:0/20:4
16:0/20:4
18:1/18:1
18:0/18:1
p16:0/22:6
p16:0/22:5
p18:0/20:4
16:0/22:6
18:1/20:4
18:0/20:3
p18:0/22:6
18:1/22:6
18:0/22:4

0.038
0.019
0.105
0.213
0.037
0.084
0.071
0.361
0.144
0.327
0.583
0.106
0.116
0.497
0.166
0.210

(0–0.077)
(−0.005 to 0.042)
(−0.029 to 0.238)
(0.131–0.295)
(0.005–0.068)
(−0.046 to 0.214)
(0.011–0.131)
(0.218–0.504)
(0.069–0.219)
(0.173–0.261)
(0.415–0.751)
(0.086–0.126)
(0.076–0.156)
(0.265–0.728)
(0.113–0.220)
(0.084–0.337)

FAS GOF (95% conﬁdence interval); n = 6
0.019
0.020
0.057
0.248
0.050
0.016
0.072
0.336
0.182
0.261
0.608
0.197
0.130
0.546
0.152
0.135

(0.008–0.029)
(0.008–0.032)
(0.037–0.076)
(0.192–0.303)
(0.024–0.076)
(0.011–0.022)
(0.046–0.098)
(0.281–0.391)
(0.131–0.234)
(0.196–0.326)
(0.453–0.762)
(0.114–0.279)
(0.090–0.171)
(0.421–0.671)
(0.137–0.168)
(0.086–0.183)

p
0.356
0.915
0.501
0.506
0.538
0.331
0.970
0.753
0.425
0.455
0.837
0.062
0.633
0.721
0.631
0.302

Synaptic membranes isolated by sucrose gradient were analyzed by electrospray ionization mass spectrometry. Identiﬁed peaks were normalized to input protein content and to an
internal standard. Mice were either 6-month-old Fasn+/+ (control) or age-matched FasnR1812W/R1812W (FAS GOF). Groups were compared by two-tailed homoscedastic t test.

responses. For example, in dorsal root ganglia cultures, lipotoxicity because of excess SFAs—palmitate in particular—
contributes to neural dysfunction through mitochondrial
damage (39). Alternatively, membrane lipid changes could
directly impact second messenger signaling, for example,
through changes in arachidonic acids or epoxyeicosatrienoic
acids, which are known to mediate neurovascular crosstalk in
the retina (40). Studies designed to monitor small-scale
vascular caliber changes reproducibly show that experimental and clinical diabetes reduces light-stimulated vasodilation in the retina. Lipogenic pathways impacted by diabetes
may account for such changes by directly modifying the
metabolic demands and signaling characteristics of photoreceptors. Exploring this possibility could identify a novel target
for early therapeutic intervention in DR.

Elevated
Intracellular
Glucose

P
De-phosphorylation
(ACTIVE)

Diabetes

ACC

FAS
NADPH

Acetyl CoA

Malonyl-CoA
Acetyl CoA

ELOVL4

NADP+

Palmitate

Oleate,
Other SFAs

DHAs, EPAs,
Other VLC-PUFAs
SCD2

Figure 5. A model for FAS activity in photoreceptors in early diabetes.
Diabetes-induced increases in photoreceptor glucose concentration result
in dephosphorylation (disinhibition) of acetyl-CoA carboxylase (ACC), which
in turn increases production of malonyl-CoA—a substrate and allosteric
activator of FAS. FAS-mediated production of palmitate promotes subsequent enzymatic reactions that are responsible for production of longer
chain saturated fatty acids (SFAs) and unsaturated fatty acids. Simultaneous
changes in diabetes, such as reduction in docosahexaenoic acid (DHA),
eicosapentaenoic acid (EPA), and other very-long chain polyunsaturated
fatty acids (VLC-PUFAs), mediated by suppressed expression of factors such
as elongation of VLC fatty acids protein 4 (ELOVL4) and stearyl-CoA desaturase 2 (SCD2), may work in concert to produce membrane changes in the
retina to cause pathology in diabetes. FAS, fatty acid synthase.
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Experimental procedures
Animals
C57BL/6J mice were obtained from Jackson Laboratories
(stock no. 000664) and were free of rd1 or rd8 mutations.
Leptin receptor mutation-carrying BKS.Cg-Dock7m +/+
Leprdb/J breeding pairs (db/m heterozygotes) were also obtained from Jackson Laboratories (stock no. 000642). F1
progeny were generated with the following expected ratios:
25% homozygous db/db animals, which are spontaneously
diabetic; 50% db/m heterozygous littermates, which are
metabolically healthy; and 25% homozygous m/m mice, which
were routinely discarded. Animals were fed Purina 4043
“chow” (13% kcal from fat, 62% kcal from carbohydrate, and
25% kcal from protein) or Harlan Teklad TD 88137 “HFD”
(42% kcal from fat, 43% kcal from carbohydrate, and 15% kcal
from protein).
In some experiments, STZ was used to induce diabetes in
male mice only, given the known resistance of female C57BL/
6J mice to this drug. To do so, 2-month-old mice were fasted
for 4 h and then given intraperitoneal doses of STZ, 60 mg/kg
dissolved in freshly prepared sodium citrate buffer (pH 4.5) or
citrate buffer alone for controls. The procedure was repeated
every 24 h for a total of ﬁve doses. Random blood glucose was
assessed weekly by a portable Glucocard test-strip device
(Arkray USA, Inc) using a drop of blood from tail-vein
puncture, beginning 1 week after STZ dosing. Animals with
glucose values consistently above 300 mg/dl were considered
“diabetic.” Weekly body weight was also monitored, and animals with >10% reduction in body weight compared with preSTZ baseline measurements received regular insulin therapy
(2.5 IU/kg in 0.9% NaCl by intraperitoneal administration
twice a day) to prevent excess catabolism.

Antibodies and quantitative PCR
For Western blotting, we used polyclonal rabbit immunoglobulin G (IgG) against FAS (catalog no. ab22759; AbCam),
rabbit IgG against ACC phosphorylated at Ser79 (catalog no.
3661; Cell Signaling), rabbit IgG against total ACC (catalog no.
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3662; Cell Signaling), and mouse monoclonal IgG1 against
pan-Akt (catalog no. 2920; Cell Signaling).
At the indicated ages, total RNA was extracted from isolated
retinas. After reverse transcription from 0.5 μg of input,
quantitative PCR was performed on the resulting complementary DNA using the following primer pairs.
Fasn sense 50 -GTCGTCTGCCTCCAGAGC-30 ; Fasn antisense 50 -GTTGGCCCAGAACTCCTGTA-30
Vascular endothelial growth factor-a: sense 50 -AATG
CTTTCTCCGCTCTGAA-30 ; antisense 50 -GCTTCCTACAG
CACAGCAGA-30
Intercellular adhesion molecule 1: sense 50 -AACAGTTCACCTGCACGGAC-30 ; antisense 50 -GTCACCGTTGTGAT
CCCTG-30
Inos: sense 50 -TGAAGAAAACCCCTTGTGCT-30 ; antisense 50 -TTCTGTGCTGTCCCAGTGAG-30
Gfap: sense 50 -TTTCTCGGATCTGGAGGTTG-30 ; antisense 50 -AGATCGCCACCTACAGGAAA-30
Gapdh: sense 50 -TGCACCACCAACTGCTTAGC-30 ; antisense 50 -GGCATGGACTGTGGTCATGAG-30
Rpl32: sense 50 -GGCTTTTCGGTTCTTAGAGGA-30 ;
antisense 50 -TTCCTGGTCCACAATGTCAA-30
Gene expression data were normalized to the mean of two
internal controls—Gapdh and Rpl32.
FAS enzyme activity
Two isolated retinas per animal were homogenized in lysis
buffer and centrifuged as aforementioned. One hundred microliters of supernatant was added to a buffer containing 0.1 M
potassium phosphate buffer (pH 7.0), 1 mM acetyl-CoA, 1 mM
cold malonyl-CoA, 0.1 μCi 14C-malonyl-CoA (catalog no.
NEC612005UC; PerkinElmer), 1 mM dithiothreitol, 1 mM
EDTA, and 0.5 mM freshly prepared NADPH. This mixture
was incubated in a 37  C agitating bath for 15 min, and reactions were then terminated using 7.5 μl of 60% perchloric
acid with immediate vortexing. The resulting cloudy mixture
was treated with 0.25 ml of absolute ethanol. Then, 0.75 ml
petroleum ether was added, and the mixture was agitated and
centrifuged to generate an organic phase containing longchain fatty acids. Three such extractions with petroleum
ether were performed, and the pooled organic phase was added
to a scintillation counter to quantitate the radiolabel.
Retinal morphologic assays
Eyes from male and female mice were ﬁxed in 4% paraformaldehyde at 4  C for 48 h, parafﬁn embedded, sectioned
into four micron slices, and stained with hematoxylin and
eosin.
ERG
A UTAS BigShot System (LKC Technologies, Inc) was used.
Mice (>5 for each group) were dark-adapted overnight. Under
red-light illumination, animals were anesthetized with ketamine (80 mg/kg total body weight) and xylazine (15 mg/kg of
lean body weight). Pupils were dilated with 1% atropine sulfate;
body temperature was maintained at 37  C with a heating pad;

and contact lens electrodes were placed on both eyes along
with appropriate reference and ground electrodes. The stimulus was a 10-μs full-ﬁeld white-light ﬂash. Repeated trials
were averaged for each luminance, with ten repeats used for
the dimmest ﬂashes and ﬁve repeats for the brightest ﬂashes.
Raw data were processed using a MATLAB program (MathWorks). The amplitude of the a-wave was measured from the
average pretrial baseline to the most negative point of the
average trace, and the b-wave amplitude was measured from
that point to the highest positive point. The log luminance of
the stimulus (log[cd⋅s/m2]) was calculated based on manufacturer’s calibrations. OPs were isolated using a digital Butterworth 100 Hz high-pass ﬁlter, and time to peak for each OP
(OP1–OP4) was determined.
Lipid analyses by electrospray ionization mass spectrometry
Two retinas from each animal were freshly isolated, pooled
into 500 μl of 40% methanol, and homogenized in a glass tube
with a Dounce homogenizer. An aliquot of each homogenate
(50 μl) was reserved and diluted in deionized water to 10%
methanol for total protein measurement using Bradford reagent. Using the remaining homogenate, an appropriate
amount of 14:0/14:0-PC and 14:0/14:0-PE internal standard
was added before Folch extraction. After extraction, the
organic layer was collected, dried under nitrogen, and reconstituted in 200 μl chloroform/methanol (1:1) with 0.1%
NH4OH. A 10-μl aliquot was loop injected into a Thermo
Vantage triple quadrupole mass spectrometer using an Accela
autosampler with 1250 HPLC pump, which delivered a constant ﬂow of 40 μl/min of methanol with 0.1% NH4OH. Analyses of PC species were carried out in the positive ion mode
using precursor scan of 184 with a collision energy of 33 eV to
detect the molecular species as the [M + H]+ ions. PE species
were detected as the [M − H]− ions in the negative ion mode
using precursor ion scan of 196 with a collision energy of
50 eV. Quantitation of each individual PC and PE species was
compared with internal standards, and results were normalized to the total protein content of the input.
Isolation of synaptic membranes
To isolate light membrane fractions enriched for synaptic
components, dissected retinas (two from each animal, combined) were lysed in 500 μl of high pH buffer containing
500 mM sodium carbonate (pH 11.0) and protease inhibitors
(Roche), incubated on ice for 30 min, and homogenized by
sonication at 25% amplitude for 20 s with a 50% duty cycle.
Homogenates were adjusted to 800 μl of 45% sucrose and
placed under sucrose layers of 5% (450 μl) and 35% (1 ml).
After centrifugation at 39,000 rpm in an SW-41 rotor (Beckman) at 4  C for 16 h, 200-μl fractions were sequentially
collected from top to bottom. Fractions were analyzed by SDSPAGE and immunoblotting. The ﬁrst ﬁve fractions were
combined as the light membrane component, and the next ﬁve
fractions were considered the heavy membrane component.
Combined fractions were subjected to Folch total lipid
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extraction and analyzed by electrospray ionization mass
spectrometry as described previously.
Statistics
In line graphs, data are expressed as mean ± SEM. In boxand-whisker plots, data are expressed as median, with the
box showing the limits of the interquartile range, and whiskers
representing maxima and minima. For experiments with two
groups in the independent variable, analyses were performed
using two-tailed t tests without post hoc correction. For experiments with more than two groups in the independent
variable, one-way ANOVA with Bonferroni correction was
used when only one dependent variable was present, and twoway ANOVA with Bonferroni post tests was used when two or
more dependent variables were present. All calculations were
performed using GraphPad Prism 6.0 software (GraphPad
Software, Inc). In all experiments, * indicates p < 0.05, **p <
0.01, ***p < 0.001, and ****p < 0.0001.
Study approval
Protocols followed the Association for Research in Vision
and Ophthalmology Statement for the Use of Animals and
were approved by Washington University.
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Rajagopal.
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